Zydus Cadila on Friday announced it has received approval from the Drug Controller General of India (DCGI) for emergency use of its drug ‘Virafin’ for treating moderate cases of COVID-19 in adults. According to Cadila Health, one dose of Pegylated Interferon Alpha-2b, ‘Virafin’ showed clinical and virological improvement in moderate COVID-19 cases.The Ahmedabad-based pharmaceutical firm said 91.15 per cent of patients treated with PegIFN were RT-PCR negative by day 7. The treatment significantly reduces the hours of supplemental oxygen in the patients, it said.

Zydus Cadila on Friday announced it has received approval from the Drug Controller General of India (DCGI) for emergency use of its drug ‘Virafin’ for treating moderate cases of COVID-19 in adults. According to Cadila Health, one dose of Pegylated Interferon Alpha-2b, ‘Virafin’ showed clinical and virological improvement in moderate COVID-19 cases.The Ahmedabad-based pharmaceutical firm said 91.15 per cent of patients treated with PegIFN were RT-PCR negative by day 7. The treatment significantly reduces the hours of supplemental oxygen in the patients, it said.